Member-only story
Artificial Intelligence in Pharma
AI will change the way we are being treated medically
Few activities around Pharma could be more clinically meaningful than drug discovery, repurposing, new drug development and pharmaceutical optimization. Well-known companies such as Pfizer, Merck, GlaxoSmithKline, Bristol-Myers Squibb, Eli Lilly, Novartis, Roche, Novartis Clinical Research, and many more have adopted AI to fill gaps in their database and to make recommendations for potential new drugs. Even the National Institutes of Health is starting to build a computational database of the pharmaceutical products that have gone to market. Large pharmaceutical companies are incorporating AI into their business workflow in real time, as IBM has demonstrated with IBM Watson.
Enhance our access to clinical drug data
Within the past few years, there has been a renewed interest in clinical drug development and a growing network of clinical-based expertise focused on high-value clinical discoveries. Whether from cardiovascular, infectious disease, genetic, or cancer concerns, the growing number of clinical drug concepts discovered in clinical trials continues to stimulate and enhance our access to high-value patient-initiated clinical research.
